The purposes of this study were to assess the correlation between the plasma level of Hsp90α and the clinicopathological characteristics of patients with liver cancer and compare the diagnostic efficacy of Hsp90α, AFP, CEA, and CA199 in HCC. A total of 200 individuals, including 140 patients with liver cancer or benign liver diseases and 60 healthy people, were enrolled for quantitative measurement of plasma Hsp90α by ELISA. The plasma level of Hsp90α was significantly different between patients with liver cancer or benign liver diseases and healthy controls (P < 0.001). The sensitivity, specificity, and AUC (95% CI) of Hsp90α were 93.2%, 85.4%, and 0.931% (0.891–0.972%), respectively, when Hsp90α was applied to differentiate liver cancer patients and healthy controls. Significant positive correlations between the plasma Hsp90α level and clinicopathological characteristics such as the history of basic liver disease (P = 0.038), active stage of hepatitis (P = 0.039), Child-Pugh score (P < 0.001), size of focal liver lesions (P = 0.004), and extrahepatic metastasis (P < 0.001) were observed. AFP + Hsp90α was the best combination strategy for the auxiliary diagnosis of HCC, with a sensitivity of 95.7%, a specificity of 97.5%, and an AUC of 0.990 (0.976–1.000). The level of plasma Hsp90α decreased significantly (P < 0.001) after resection of tumor tissue. This study demonstrated that plasma Hsp90α levels are useful as a diagnostic biomarker in liver cancer and may predict the responses of patients with liver cancer to surgery. Some clinicopathological characteristics could affect the plasma Hsp90α levels.

中文翻译：

---

血浆热休克蛋白 90alpha 作为肝癌诊断的生物标志物：在不同临床病理特征的患者中

本研究的目的是评估血浆 Hsp90α 水平与肝癌患者临床病理特征的相关性，并比较 Hsp90α、AFP、CEA 和 CA199 对 HCC 的诊断功效。共纳入200人，其中肝癌或良性肝病患者140人，健康人60人，采用ELISA定量测定血浆Hsp90α。Hsp90α的血浆水平在肝癌或良性肝病患者与健康对照组之间存在显着差异（P < 0.001）。当 Hsp90α 用于区分肝癌患者和健康对照时，Hsp90α 的敏感性、特异性和 AUC（95% CI）分别为 93.2%、85.4% 和 0.931%（0.891-0.972%）。血浆Hsp90α水平与基础肝病史（P=0.038）、肝炎活动期（P=0.039）、Child-Pugh评分（P<0.001）、肝脏局灶性病变大小等临床病理特征呈显着正相关(P = 0.004) 和肝外转移 (P < 0.001) 被观察到。AFP+Hsp90α是辅助诊断HCC的最佳组合策略，敏感性为95.7%，特异性为97.5%，AUC为0.990（0.976-1.000）。切除肿瘤组织后血浆 Hsp90α 水平显着降低（P < 0.001）。该研究表明，血浆 Hsp90α 水平可用作肝癌的诊断生物标志物，并可预测肝癌患者对手术的反应。一些临床病理特征会影响血浆 Hsp90α 水平。